1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Drugs In Development, 2022, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 1, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 3 molecules, respectively.
Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hepatitis D - Overview
- Hepatitis D - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hepatitis D - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatitis D - Companies Involved in Therapeutics Development
- Albireo Pharma Inc
- Antios Therapeutics Inc
- CN Bio Innovations Ltd
- Eiger BioPharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Globeimmune Inc
- Huahui Anjian (Beijing) Biotechnology Co Ltd
- Johnson & Johnson
- Merck & Co Inc
- PharmaEssentia Corp
- Replicor Inc
- Rodos BioTarget GmbH
- SomaGenics Inc
- Svenska Vaccinfabriken Produktion AB
- Vir Biotechnology Inc
- Hepatitis D - Drug Profiles
- A-2342 - Drug Profile
- Product Description
- Mechanism Of Action
- Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ATI-2173 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- bulevirtide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- daplusiran - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GI-18000 - Drug Profile
- Product Description
- Mechanism Of Action
- HH-003 - Drug Profile
- Product Description
- Mechanism Of Action
- HH-006 - Drug Profile
- Product Description
- Mechanism Of Action
- lonafarnib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- peginterferon alfa-2a - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- peginterferon lambda-1a - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RBT-05 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REP-2139 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REP-2165 - Drug Profile
- Product Description
- Mechanism Of Action
- ropeginterferon alfa-2b LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Hepatitis D - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit NTCP for Infectious Diseases and Unspecified Metabolic Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- SVF-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile
- Product Description
- Mechanism Of Action
- vanitaracin A - Drug Profile
- Product Description
- Mechanism Of Action
- VIR-2218 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VIR-3434 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hepatitis D - Dormant Projects
- Hepatitis D - Product Development Milestones
- Featured News & Press Releases
- Jun 23, 2022: Albireo announces presentation of A2342 new data in Hepatitis
- Jun 23, 2022: Treatment with Hepcludex (Bulevirtide) meets primary endpoint and achieves significant response in chronic hepatitis delta virus at 48 Weeks
- Dec 21, 2021: Eiger BioPharmaceuticals announces first patient enrolled in LIMT-2: a phase 3 study of peginterferon lambda in patients with chronic hepatitis delta virus (HDV) infection
- Dec 01, 2021: Eiger BioPharmaceuticals announces presentations on Lonafarnib at Upcoming HEP DART 2021 Meeting
- Dec 01, 2021: Eiger BioPharmaceuticals announces presentations on Peginterferon Lambda at Upcoming HEP DART 2021 Meeting
- Nov 19, 2021: Gilead submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an investigational treatment for people living with chronic hepatitis delta
- Nov 02, 2021: Eiger concludes subject enrolment in Phase III HDV drug trial
- Feb 24, 2021: VLP BioTech announces an immunotherapy designed for the treatment of chronic HBV/HDV infections
- Nov 17, 2020: Eiger announces positive Peginterferon Lambda - Lonafarnib combination end of study results from phase 2 LIFT HDV study in late-breaker session at The Liver Meeting Digital Experience 2020
- Nov 16, 2020: Eiger announces case studies demonstrating regression of liver fibrosis following 48 weeks of therapy with Peginterferon Lambda in patients with Chronic Hepatitis Delta Virus (HDV) Infection presented at The Liver Meeting Digital Experience 2020
- Nov 02, 2020: Eiger announces abstracts highlighting Peginterferon Lambda and Lonafarnib in chronic hepatitis delta virus (HDV) infection accepted for presentation at The Liver Meeting Digital Experience 2020
- Sep 17, 2020: MYR Pharmaceuticals launches HEPCLUDEX in Germany, France and Austria
- Sep 03, 2020: European Commission (EC) Grants conditional Marketing Authorization (CMA) for MYR Pharmaceuticals HEPCLUDEX
- Aug 31, 2020: Eiger announces Peginterferon Lambda - Lonafarnib combination end of treatment results from phase 2 LIFT HDV study in late breaker session at The Digital International Liver Congress 2020
- Aug 04, 2020: MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Hepatitis D, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hepatitis D - Pipeline by Albireo Pharma Inc, 2022
- Hepatitis D - Pipeline by Antios Therapeutics Inc, 2022
- Hepatitis D - Pipeline by CN Bio Innovations Ltd, 2022
- Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, 2022
- Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Hepatitis D - Pipeline by Gilead Sciences Inc, 2022
- Hepatitis D - Pipeline by Globeimmune Inc, 2022
- Hepatitis D - Pipeline by Huahui Anjian (Beijing) Biotechnology Co Ltd, 2022
- Hepatitis D - Pipeline by Johnson & Johnson, 2022
- Hepatitis D - Pipeline by Merck & Co Inc, 2022
- Hepatitis D - Pipeline by PharmaEssentia Corp, 2022
- Hepatitis D - Pipeline by Replicor Inc, 2022
- Hepatitis D - Pipeline by Rodos BioTarget GmbH, 2022
- Hepatitis D - Pipeline by SomaGenics Inc, 2022
- Hepatitis D - Pipeline by Svenska Vaccinfabriken Produktion AB, 2022
- Hepatitis D - Pipeline by Vir Biotechnology Inc, 2022
- Hepatitis D - Dormant Projects, 2022
List of Figures
- Number of Products under Development for Hepatitis D, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Albireo Pharma Inc
- Antios Therapeutics Inc
- CN Bio Innovations Ltd
- Eiger BioPharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Globeimmune Inc
- Huahui Anjian (Beijing) Biotechnology Co Ltd
- Johnson & Johnson
- Merck & Co Inc
- PharmaEssentia Corp
- Replicor Inc
- Rodos BioTarget GmbH
- SomaGenics Inc
- Svenska Vaccinfabriken Produktion AB
- Vir Biotechnology Inc
